Twist Bioscience Announces Proposed Public Offering of Common Stock

Twist Bioscience Corporation intends to offer and sell up to $100 million of shares of its common stock in an underwritten public offering.

In addition, it intends to grant the underwriters a 30-day option to purchase up to $15 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

It intends to use the net proceeds of the offering, along with its existing cash, cash equivalents and short-term investments to scale investment in its R&D organization, which includes investing in pharmaceutical biologics drug discovery and in DNA storage, to increase its investment in its commercial organization to support the growth of its NGS, synbio, pharmaceutical biologics drug discovery programs and its global expansion, to scale its NGS operations and to expand its production capacity, and the remainder for working capital and general corporate purposes.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group LLC are acting as joint book-running managers. Robert W. Baird & Co. Incorporated is acting as lead manager.